ABBVIE

Neurocrine Biosciences has launched a Phase 1 first-in-human clinical study evaluating NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist for congenital adrenal hyperplasia treatment.

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1 billion to gain access to CPTX2309, a potential first-in-class treatment for autoimmune diseases currently in Phase 1 trials.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

Allergan Aesthetics has received FDA acceptance for review of its supplemental premarket approval application to expand SKINVIVE by Juvéderm's indication from cheek smoothness to include neck line treatment.

Simcere Zaiming has dosed the first US patient in a Phase 1 trial of SIM0500, a trispecific antibody targeting GPRC5D, BCMA, and CD3 for relapsed/refractory multiple myeloma treatment.

Avalo Therapeutics has appointed Rita Jain, M.D., a rheumatologist with over two decades of biopharmaceutical leadership experience, to its Board of Directors.

AbbVie's migraine prevention drug Qulipta showed significantly lower discontinuation rates compared to topiramate in a late-stage head-to-head trial, with only 12.1% of patients stopping treatment versus 29.6% for the generic drug at 24 weeks.

Bavarian Nordic announced the sale of its Priority Review Voucher for $160 million, awarded following FDA approval of its chikungunya vaccine VIMKUNYA in February 2025.

AbbVie's Phase 3 TEMPLE study shows atogepant (QULIPTA/AQUIPTA) achieved significantly fewer treatment discontinuations due to adverse events compared to topiramate for migraine prevention.

Senate Republicans excluded the Orphan Cures Act from their version of Trump's "One Big Beautiful Bill Act," removing provisions that would have exempted multi-indication orphan drugs from Medicare price negotiations.